ESMO: Despite positive trial, Merck's Welireg still comes up short in overall survival

[cafead]

via One year after reporting a split result on Merck’s Welireg in a key phase 3 trial, the song remains the same for the kidney cancer drug as it continues to show benefits in progression-free survival (PFS) but no significant improvement in overall survival (OS) when compared to Novartis’ chemotherapy Afinitor.

article source